Experimental drug aims to shield kidneys in sepsis patients

NCT ID NCT07215702

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 5 times

Summary

This study tests an experimental drug called AZD4144 in 124 adults with sepsis who have also developed acute kidney injury. Participants receive either the drug or a placebo daily by IV while in the hospital. The main goal is to see if the drug helps maintain kidney function better than placebo. Researchers will also track how many days patients stay alive and free from dialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: AZD4144 (an experimental drug given intravenously)
What this could lead to: If it works, this could point toward a treatment to protect kidney function in sepsis patients and reduce the need for dialysis.
What could go wrong: This is an early Phase 2 trial with only 124 participants, so results may not confirm benefit. The drug may not improve kidney outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 124 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Age ≥ 18 to ≤ 80 years at the time of signing the informed consent. Participants who are admitted to an ICU or an equivalent critical-care unit. Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on: A. Suspected or confirmed bacterial infection AND B. Acute increase of mSOFA score of 2 or more excluding renal component (change in score measured to account for participants that may meet mSOFA criteria from pre-existing organ dysfunction before the onset of infection). Haemodynamic therapy: A. 30 mL/kg or clinically appropriate volume resuscitation prior to randomisation. B. Vasopressor and/or inotrope therapy for sepsis-induced hypotension (eg, norepinephrine \[noradrenaline\], epinephrine \[adrenaline\], phenylephrine, dopamine, dobutamine) for ≥ 4 hours. Diagnosis of AKI, within 72 hours of sepsis diagnosis, with modified KDIGO Stage ≥ 1, defined as: Increase in SCr to ≥ 1.5 × baseline (outpatient \[preferred\] or admission pre-AKI reference). Timing of AKI diagnosis is defined as the time that the initial qualifying SCr was reported. AKI must persist after completion of initial volume resuscitation (30 mL/kg or as clinically indicated per investigator discretion). Outpatient pre-AKI reference eGFR ≥ 30 mL/min/1.73 m2, if available within 2 weeks to 12 months prior to admission (preferred). If not available, admission pre-AKI reference eGFR ≥ 45 mL/min/1.73 m2 . Body weight ≥ 40 kg or ≤ 125 kg. Female or male, assigned at birth, inclusive of all gender identities. All FOCBP must have a negative pregnancy test at the Screening visit (Visit 1). Contraception: A. Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods detailed in CSP from the time of first administration of study intervention administration until 100 days after the last dose of study intervention. B. FOCBP must not be lactating and must agree to use an approved method of highly effective contraception, as detailed in the CSP from the time of first administration of study intervention until 100 days after last dose of study intervention. Capable of giving signed informed consent (participant or LAR). Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research. Exclusion Criteria Any clinical evidence which in the investigator's opinion makes it undesirable for the potential participant to enrol in the study. Known history of Stage 4 or 5 CKD with documented sustained eGFR \< 30 mL/min/1.73 m2 prior to hospital admission. Sepsis diagnosed \> 7 days after hospital admission (to include from time of outside admission if patient transferred from another healthcare setting). AKI attributed to causes other than sepsis, including but not limited to compromised renal perfusion-related causes (surgical complication, acute abdominal aortic aneurysm, dissection, renal artery stenosis, etc), glomerular disease, acute interstitial nephritis, and medication toxicity. Evidence of recovery from AKI prior to randomisation defined as: A. A reduction of SCr to less than 1.5 times reference SCr in the last available local SoC laboratory result before randomisation or B. A \> 25% reduction in SCr from peak SCr after volume resuscitation prior to randomisation. Expected survival from sepsis \< 24 hours. Expected survival \< 90 days due to chronic or pre-existing medical conditions other than SA-AKI Known history of renal transplant or bilateral nephrectomy. Permanent incapacitation. Incapacitation is defined as the inability to independently perform tasks essential to personal health and/or safety. Active cancer or cancer in remission for less than 2 years. Known history of immunodeficiency disease or currently receiving immunosuppressant therapy for non-sepsis related disease. Severe burns requiring ICU treatment. Sepsis attributed to confirmed or presumed fungal or viral infection at time of Screening. Has advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C). Known history of cerebrovascular accident within the last 90 days. Known history of heart failure with reduced ejection fraction with documented ejection fraction ≤ 20% before sepsis diagnosis. Known hypersensitivity to iohexol or known history of severe adverse reaction to iodinated contrast media. Participants with known medical or psychological condition(s), or who, in the judgement of the investigator, should not participate in the study if they are unlikely to comply with study procedures, restrictions, and requirements. Current KRT (eg, continuous haemofiltration and haemodialysis/continuous kidney replacement therapy, intermittent haemodialysis, and peritoneal dialysis) or planned KRT (meaning KRT is scheduled, or the decision to initiate KRT has been made by the treating physician) at randomisation. Currently receiving active treatment for malignancy. Potential participants will be excluded if they have received a certain class of medication during the weeks before enrollment or are anticipated to require a specific class of medication during the trial duration. Participants with a known hypersensitivity to AZD4144 or any of the excipients of the product. Receipt of another IMP within 30 days, 5 half-lives, or the time frame of expected PD effect from most recent dose, whichever is longest. Previous receipt of AZD4144. Active or planned treatment of sepsis with an extracorporeal haemoperfusion device. Participation in any other concurrent ICU study which could impact participant clinical outcomes and confound results of this study to, including but not limited to volume resuscitation, vasopressor, or mechanical ventilation studies. Presence of anuria (≥ 12 hours) at randomisation. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead ECG, at Screening, as judged by the investigator. Prolonged QTcF \> 470 ms. Known history of QT prolongation associated with other medications that required discontinuation of that medication. Congenital long QT syndrome. Known history of ST-elevation myocardial infarction or non-ST-elevation myocardial infarction, with or without intervention by percutaneous coronary intervention or coronary artery bypass grafting within the last 90 days. Ventricular arrhythmia requiring treatment. Known or presumed latent or active tuberculosis. Acute pancreatitis with no established source of infection. Undergoing extracorporeal membrane oxygenation (ECMO) at randomisation. Neutropenia: ANC \< 1.5 × 109/L. Admitting diagnosis of rhabdomyolysis. Admitting diagnosis of trauma with CK \> 15000 U/L. Presumed nidus of infection in central nervous system. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). Previous randomisation in the present study. For females only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding. First infusion of IMP unable to be started within 36 hours of AKI diagnosis. Presence of a do-not-resuscitate order.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Sepsis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

63 sites in 13 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Research Site
NOT_YET_RECRUITING

Phoenix, Arizona, 85006, United States
Research Site
RECRUITING

Newport Beach, California, 92663, United States
Research Site
RECRUITING

Kansas City, Kansas, 66160, United States
Research Site
NOT_YET_RECRUITING

Baltimore, Maryland, 21205, United States
Research Site
RECRUITING

Boston, Massachusetts, 02115, United States
Research Site
RECRUITING

Detroit, Michigan, 48202, United States
Research Site
RECRUITING

The Bronx, New York, 10451, United States
Research Site
RECRUITING

The Bronx, New York, 10461, United States
Research Site
RECRUITING

The Bronx, New York, 10467, United States
Research Site
NOT_YET_RECRUITING

Chapel Hill, North Carolina, 27519, United States
Research Site
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Research Site
WITHDRAWN

Corvallis, Oregon, 97330, United States
Research Site
RECRUITING

Philadelphia, Pennsylvania, 19140, United States
Research Site
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Research Site
RECRUITING

Charleston, South Carolina, 29402, United States
Research Site
WITHDRAWN

Salt Lake City, Utah, 84107, United States
Research Site
WITHDRAWN

CABA, 1430, Argentina
Research Site
RECRUITING

Ciudad de Buenos Aires, C1180AAX, Argentina
Research Site
RECRUITING

La Plata, B1900AVG, Argentina
Research Site
RECRUITING

Rosario, 2000, Argentina
Research Site
RECRUITING

Brussels, 1200, Belgium
Research Site
RECRUITING

Genk, 3600, Belgium
Research Site
RECRUITING

Jette, 1090, Belgium
Research Site
RECRUITING

Ottignies, 1340, Belgium
Research Site
RECRUITING

Lévis, Quebec, G6V 3Z1, Canada
Research Site
WITHDRAWN

Montreal, Quebec, H1T 2M4, Canada
Research Site
RECRUITING

Montreal, Quebec, H2X 3E4, Canada
Research Site
RECRUITING

Montreal, Quebec, H4J 1C5, Canada
Research Site
RECRUITING

Québec, Quebec, G1R 2J6, Canada
Research Site
NOT_YET_RECRUITING

Québec, Quebec, G1V 4G5, Canada
Research Site
NOT_YET_RECRUITING

Brno, 656 91, Czechia
Research Site
RECRUITING

Kolín, 280 02, Czechia
Research Site
WITHDRAWN

Prague, 128 08, Czechia
Research Site
RECRUITING

Prague, 18000, Czechia
Research Site
WITHDRAWN

Aarhus N, 8200, Denmark
Research Site
RECRUITING

Gistrup, 9260, Denmark
Research Site
RECRUITING

Hvidovre, 2650, Denmark
Research Site
WITHDRAWN

Angers, 49033, France
Research Site
NOT_YET_RECRUITING

Brive-la-Gaillarde, 19100, France
Research Site
RECRUITING

La Roche-sur-Yon, 85925, France
Research Site
RECRUITING

Limoges, 87000, France
Research Site
RECRUITING

Strasbourg, 67091, Cedex, France
Research Site
RECRUITING

Tours, 37044, France
Research Site
RECRUITING

Aachen, 52074, Germany
Research Site
NOT_YET_RECRUITING

Essen, 45147, Germany
Research Site
RECRUITING

Frankfurt, 60590, Germany
Research Site
RECRUITING

Greifswald, 17475, Germany
Research Site
RECRUITING

Heidelberg, 69120, Germany
Research Site
RECRUITING

Kiel, 24105, Germany
Research Site
RECRUITING

Leipzig, 04103, Germany
Research Site
NOT_YET_RECRUITING

Münster, 48149, Germany
Research Site
RECRUITING

Athens, 11527, Greece
Research Site
RECRUITING

Thessaloniki, 54642, Greece
Research Site
NOT_YET_RECRUITING

Budapest, 1082, Hungary
Research Site
NOT_YET_RECRUITING

Debrecen, 4032, Hungary
Research Site
NOT_YET_RECRUITING

Kaposvár, 7400, Hungary
Research Site
NOT_YET_RECRUITING

Pécs, 7624, Hungary
Research Site
NOT_YET_RECRUITING

Szeged, 6725, Hungary
Research Site
NOT_YET_RECRUITING

Tatabánya, 2800, Hungary
Research Site
WITHDRAWN

Milan, 20122, Italy
Research Site
WITHDRAWN

Padua, 35128, Italy
Research Site
WITHDRAWN

Roma, 00168, Italy
Research Site
WITHDRAWN

Rozzano, 20089, Italy
Research Site
RECRUITING

Barcelona, 08035, Spain
Research Site
RECRUITING

Jerez de la Frontera, 11407, Spain
Research Site
RECRUITING

Valencia, 46026, Spain
Research Site
RECRUITING

Adapazarı, 54290, Turkey (Türkiye)
Research Site
RECRUITING

Ankara, 06800, Turkey (Türkiye)
Research Site
RECRUITING

Kahramanmaraş, 46100, Turkey (Türkiye)
Research Site
RECRUITING

Kocaeli, 41380, Turkey (Türkiye)
Research Site
RECRUITING

Brighton, BN2 5BE, United Kingdom
Research Site
RECRUITING

Guildford, GU27XX, United Kingdom
Research Site
RECRUITING

Liverpool, L7 8XP, United Kingdom
Research Site
RECRUITING

London, SE1 7EH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.